Policy #	Policy Name	Type of Change	Brief Description of Policy Change	Reason for Changes
UM ONC_1132	Rituxan Products		Annual Review	
UM ONC_1180	Immune Globulin (IG)		Annual Review	
UM ONC_1196	Sprycel (dasatinib)		Annual Review	
UM ONC_1199	Tasigna (nilotinib)		Annual Review	
UM ONC_1206	Xalkori (crizitinib)		Annual Review	
UM ONC_1221	Bosulif (bosutinib)		Annual Review	
UM ONC_1225	Voraxaze (glucarpidase)		Annual Review	
UM ONC_1243	Nplate (romiplostim)		Annual Review	
UM ONC_1244	Promacta (eltrombopag)		Annual Review	
UM ONC_1272	Ibrance (palbocidib)		Annual Review	
UM ONC_1299	Tecentriq (atezolizumab)		Annual Review	
 UM ONC_1303	Xermelo (telotristat ethyl)		Annual Review	
UM ONC 1316	Nerlynx (meratinib)		Annual Review	
UM ONC 1323	Idhifa (enasidenib)		Annual Review	
UM ONC 1328	Verzenio (abemaciclib)		Annual Review	
 UM ONC_1333	Erleada (apalutamide)		Annual Review	
UM ONC_1345	Tavalisse (fostamatinib)			
	Prev. UM_1047		Annual Review	
UM ONC_1362	Polivy (polatuzumab vedotin)		Annual Review	
UM ONC_1412	Monjuvi (tafasitamab-cxix)		Annual Review	
UM ONC_1415	Jelmyto (mitomycin for pyelocalyceal installation)		Annual Review	
UM ONC_1434	Zynlonta (loncastuzimab tesirine-lpyl)		Annual Review	
UM ONC_1443	Mozobil (plerixafor)		Annual Review	
UM ONC_1448	Ferriprox (deferiprone)		Annual Review	